ClinicalTrials.Veeva

Menu

Gene Transfer Clinical Study in X-Linked Myotubular Myopathy (ASPIRO)

Astellas logo

Astellas

Status and phase

Active, not recruiting
Phase 3
Phase 2

Conditions

X-Linked Myotubular Myopathy

Treatments

Genetic: Resamirigene bilparvovec

Study type

Interventional

Funder types

Industry

Identifiers

NCT03199469
2024-512637-32 (Other Identifier)
ATX-MTM-002

Details and patient eligibility

About

This was a multinational, open-label, ascending-dose, delayed-treatment concurrent control clinical study to evaluate the safety and efficacy of resamirigene bilparvovec in participants with X-Linked Myotubular Myopathy aged less than 5 years old. Participants received a single dose of resamirigene bilparvovec and followed for safety and efficacy for 10 years

Full description

This study evaluated safety and efficacy of gene transfer in X-Linked Myotubular Myopathy. Participants received a single dose of resamirigene bilparvovec delivered intravenously.

ASPIRO was being conducted in two parts. Part 1 was a dose escalation phase that was evaluating the preliminary safety and efficacy of Resamirigene bilparvovec at doses of 1.3x10^14 vg/kg and 3.5x10^14 vg/kg. Part 2 of ASPIRO was a pivotal expansion cohort designed to confirm the safety and efficacy of resamirigene bilparvovec at a dose of 3.5x10^14 vg/kg. The pivotal expansion cohort enrolled eight participants, consisting of four age-matched pairs (within +/- 6 months of age). One participant from each pair was randomized to receive a single dose of resamirigene bilparvovec at 3.5x10^14 vg/kg, and the other served as a delayed treatment control. Eligible delayed treatment control participants administered resamirigene bilparvovec after that individual participant completed the Week 24 visit as a delayed treatment control.

The primary efficacy endpoint measures assessed at Week 24. Participants were followed for a total of 10 years after administration of resamirigene bilparvovec. Only Part 1 of the study was reported.

This study utilized an independent Data Monitoring Committee (DMC) that monitored participant safety and provided recommendations to Astellas regarding dose escalation, dose expansion, and safety matters.

Enrollment

27 patients

Sex

Male

Ages

Under 5 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject has a diagnosis of XLMTM resulting from a genetically confirmed mutation in the MTM1 gene as assessed by a Sponsor-approved testing facility.
  • Subject is male.
  • Subject is aged less than 5 years old at dosing
  • Subject requires mechanical ventilatory support:

Part 1: Subject requires some mechanical ventilatory support (e.g., ranging from 24 hours per day full time mechanical ventilation, to noninvasive support such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) during sleeping hours).

Part 2: Subject requires invasive mechanical ventilatory support ranging from 20 - 24 hours per day at screening (confirmed by daytime polysomnographic study).

  • Subject requiring invasive mechanical ventilator support is fitted with or willing to be fitted with a cuffed tracheostomy tube for some respiratory assessments.
  • Subject has ventilator maximum positive end-expiratory pressure (PEEP) <8 cm H2O at screening.
  • UNIQUE to France: Subject's weight is ≥ 4.8 kg.

Exclusion criteria

  • Subject is participating in an interventional study designed to treat XLMTM.
  • Subject born <35 weeks gestation who is still not term as per corrected age.
  • Subject tests positive for AAV8 neutralizing antibody with titers above protocol specified threshold.
  • Subject had recent surgery (<3 months before Day 1) or has planned surgery that may confound data collection during the first 48 weeks of the study.
  • Subject has a clinically important condition other than XLMTM in the opinion of the investigator.
  • Subject has a clinically significant underlying liver disease.
  • Subject is currently experiencing a clinically important respiratory infection or other active infection.
  • Subject has received pyridostigmine or any medication to treat XLMTM within 3 months before Day 1.
  • Other than as required per protocol, subject has received immune-modulating agents within 3 months before Day 1 (use of inhaled corticosteroids to manage chronic respiratory conditions is allowed); use of other concomitant medications to manage chronic conditions must have been stable for at least 4 weeks before dosing.
  • Subject has a contraindication to prednisolone.
  • Subject has a contraindication to study drug or ingredients.
  • Subject has previous scoliosis repair surgery/procedure, or planned/expected scoliosis repair surgery/procedure in the 12 months following Day 1 (Part 2 including any subjects enrolled under protocol v8 and beyond).
  • Subject has contractures, scoliosis, or other medical condition that would limit the potential to achieve unassisted sitting, in the opinion of the investigator (Part 2 including any subjects enrolled under protocol V8 and beyond).
  • Subject is able to sit without assistance for at least 30 seconds at screening, in the opinion of the investigator (Part 2 including any subjects enrolled under protocol V8 and beyond).
  • Subject has a clinically important condition, including CTCAE v4.03 Grade ≥ 2 anemia (< 10 g/dL hemoglobin).
  • Subject has a contraindication to ursodiol (ursodeoxycholic acid).
  • UNIQUE to France: Subject has a prior diagnosis or history of cardiac arrhythmias, myocarditis, or any other cardiac disease.
  • UNIQUE to France: Subject has a contraindication to general anesthesia and to muscle biopsy procedures.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

27 participants in 2 patient groups

1.3 × 10^14 vg/kg (Low dose)
Experimental group
Description:
Participants received 1.3 x 10\^14 viral genomes per kilogram (vg/kg) of body weight resamirigene bilparvovec as a single dose intravenously on Day 1. A sentinel dose was given to first participant and if there were no safety concerns, subsequent participants received either resamirigene bilparvovec at the same dose or control with delayed treatment after at least 4 weeks of post-dose data from the sentinel participant.
Treatment:
Genetic: Resamirigene bilparvovec
3.5 × 10^14 vg/kg (High dose)
Experimental group
Description:
Participants received 3.5 × 10\^14 vg/kg of body weight resamirigene bilparvovec as a single dose intravenously on Day 1. A sentinel dose was given to first participant and if there were no safety concerns, subsequent participants received either resamirigene bilparvovec at the same dose or control with delayed treatment after at least 4 weeks of post-dose data from the sentinel participant.
Treatment:
Genetic: Resamirigene bilparvovec

Trial documents
2

Trial contacts and locations

6

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems